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210Introduction: Active prostate cancer treatment is often associated with signiﬁcant adverse physiological and
psychological effects including signiﬁcant sexual problems. Most studied among these sexual problems is erectile
dysfunction while related sexual bothers such as overall sexual function and satisfaction with one’s sex life are
much less studied.
Aim: To investigate problems related to erectile functioning, orgasmic ability, sexual function, and satisfaction
with one’s sex life among a cohort of Scandinavian prostate cancer patients age 40 years and older who were
sexually active prior to their diagnosis of prostatic cancer.
Methods: The survey study used a cross-sectional design and a mixed recruitment procedure. Patients were
recruited through the prostate cancer patient advocate organizations in Denmark, Norway, and Sweden
(Scandinavia). The ﬁnal sample included 1,707 prostate cancer patients. For analyses, participants were stratiﬁed
into 4 groups according to their total treatment burden.
Outcomes: Outcomes included subjective reporting of erectile functioning, orgasm, and sexual functioning, and
satisfaction with one’s sex life.
Results: The study found that the prevalence of erectile dysfunction and problems related to orgasm and overall
sexual function ranged from 72e92% across prostatic cancer treatment groups. Conversely, this range was
61e69% among the respondents who had not undergone prostatic cancer treatment. Across treatment groups, a
minority of patients (<15%) reported being satisﬁed with their sex lives. After socio-demographic variables were
controlled for, patients who did not receive prostatic cancer treatment were 3.75 times more likely than those in
the reference group to not report sexual function problems.
Conclusion: Among older prostate cancer patients, who at their time of diagnose were sexually active, sexual
satisfaction is low and prevalence rates of sexual problems is high, thus underlining the strong clinical need to
address sexual problems and satisfaction among this cohort of patients in order to promote sexual health and well-
being following active cancer treatments.Martin Hald G, Dahl Pind M, Borre M, et al. Scandinavian Prostate
Cancer Patients’ Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment.
Sex Med 2018;6:210e216.
Copyright  2018, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer is the most prevalent type of male cancer in the
United States1,2 and is among the leading causes of male cancernuary 28, 2018. Accepted June 7, 2018.
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rg/10.1016/j.esxm.2018.06.002deaths worldwide with mortality being among the highest in the
Scandinavian countries.3
Active prostate cancer treatment is often associated with sig-
niﬁcant adverse physiological and psychological effects, including
muscular weakness, hot ﬂushes, reduced urinary and bowel
functioning, depression, reduced quality of life, and sexual
problems.4e9 Prostatic cancer treatment usually involves obser-
vation (active surveillance), surgery, radiation therapy, hormonal
treatment, and chemotherapy.10e12
Men with prostate cancer often experience increased rates of
sexual problems and reduced sexual functioning at baselineSex Med 2018;6:210e216
Prostate Cancer and Sexual Problems 211(pretreatment) and, most signiﬁcantly, after cancer
treatment.7,8,13e16 These problems include erectile dysfunction
(ED), reduced sexual desire, sexual pain, orgasmic problems, and
ejaculatory problems.4,13,17,18 Among these sexual problems, ED
is most commonly studied, and while other sexual problems are
less studied, they appear to be highly prevalent and bothersome
to prostate cancer patients.4,11e13 Despite the high prevalence
rates of sexual problems among prostate cancer patients, a rela-
tively limited number of large sample studies of Scandinavian
prostate cancer patients, which both focus on sexual outcomes
other than ED and differentiate results based on the most
common kinds of treatments received, exist.5 Such investigations
are important for cultural comparisons and comparison of sexual
outcomes across common treatment groups.
Sex life satisfaction and overall assessments of problems related
to sexual functioning are less studied among prostate cancer
patients compared with the vast and extensive research focuses on
speciﬁc sexual problems, dysfunctions, and quality of life more
generally.5,19e21 While there is reason to believe that sexual
functioning, sex life satisfaction, and sexual problems are inter-
related,7,22e25 according to the deﬁnition of the World Health
Organization (WHO), sexual health includes not only the absence
of sexual problems but also the presence of physiological,
emotional, psychological, and social well-being in regard to
sexuality.16,26 Therefore, where the study of more general and
speciﬁc sexual functioning problems may primarily target the
absence dimension of the WHO deﬁnition, sex life satisfaction
may be seen as targeting the presence dimension of the deﬁnition.
This double focus also seems highly relevant in studies involving
prostate cancer patients and sexuality.25,27
Among prostate cancer patients, data on sexual problems and
associated evaluative responses usually do not differentiate be-
tween those who self-identify as sexually active and those who
self-identify as non-sexually active prior to diagnosis and treat-
ment.5,17 Subgroup-speciﬁc knowledge about sexuality following
diagnosis and treatment may help provide more informed and
precise sexual intervention strategies and discussions among
health care providers and policy makers.19,28,29 Accordingly, as
most prostate cancer treatments either directly or indirectly in-
ﬂuence various aspects of sexuality,20 speciﬁc knowledge about
sexuality regarding the large (sub)group of prostate cancer pa-
tients who self-identify as sexually active prior to treatment may
be particularly clinically relevant and important.
Sociodemographic variables (eg, gender, age, relationship sta-
tus, and educational level) have been found to be associated with
various sexuality-related outcomes, including sexual problems
and bothers.16,25,30,31 Furthermore, among prostatic cancer pa-
tients, the time since diagnosis has been found to be associated
with these outcomes.6,12,17 Thus, employing analytic strategies
that consider these factors is important when studying sexual
problems among prostate cancer patients.
Based on a large Scandinavian (ie, Denmark, Norway, and
Sweden) cohort of prostate cancer patients aged 40 years andSex Med 2018;6:210e216older who self-identiﬁed as sexually active prior to receiving a
diagnosis of prostate cancer, the current study investigated
self-reported problems related to erectile functioning, orgasmic
ability, and the overall ability to function sexually. Furthermore,
among this cohort, this study also investigated overall satisfaction
with one’s sex life.METHODS
Participants
This study was part of a larger study of Scandinavian prostate
cancer patients conducted by the Scandinavian prostate cancer
patient advocate organizations.5 A total of 6,916 respondents
answered the questionnaire, and 6,200 of these questionnaires
contained valid responses (89.7%). Given our study aims, from
this sample, we selected all respondents who were 40 years of age
or older and who self-identiﬁed as sexually active prior to their
formal prostate cancer diagnosis, for a total of 1,713 respondents.
From this group, 6 respondents were excluded because they were
the only patients who received chemotherapy, resulting in a total
cohort of 1,707 respondents. The mean age of the participants
was 72.6 years (SD ¼ 7.1), with a mean of 6.1 years (SD ¼ 4.6)
since the time of diagnosis. Sample characteristics (by treatment
group) are presented in Table 1.Procedure
A mixed recruitment procedure was utilized across Scandina-
vian countries (ie, Denmark, Norway, and Sweden) to maximize
the sample size. Respondents were recruited through: (a) online
banners on the web site homepages of the Scandinavian prostate
cancer patient advocate organizations, (b) e-mails (when known)
sent directly to members of the Scandinavian prostate cancer
patient advocate organizations, and (c) paper versions of the
questionnaire made available during nationally organized pros-
tate cancer patient meetings. A professional Danish agency for
public communication was responsible for all questionnaire
distribution and collection. Following Danish rules for ethical
approval, this retrospective anonymous study was exempt from
institutional review board approval.
Respondents were invited to complete an 84-item question-
naire related to living a life with prostate cancer. The question-
naire covered patient socio-demographic data, experiences with
health care services, diagnosis and treatments, side effects, and
sexuality. The inclusion criteria was to have received a formal
diagnosis of prostate cancer. Respondents who answered fewer
than 20% of the questions and duplicates were removed from the
study.Measures
Sociodemographics
The collected sociodemographic items included: (a) country of
birth (Denmark, Norway, or Sweden); (b) age (year of birth); (c)
Table 1. Sociodemographic variables and time since prostate cancer diagnosis by treatment group
Variable Horm* No treatment* RAD* RP* Total Missing
Number of respondents 869 (50.9%) 92 (5.4%) 225 (13.2%) 521 (30.5%) 1,707
Age, y (SD) 73.6 (7.3) 76.8 (7.8) 74.0 (5.9) 69.6 (6.1) 72.6 (7.1) 0 (0%)
Time since diagnosis, y (SD) 6.3 (5.0) 5.7 (4.8) 6.3 (4.0) 5.6 (4.1) 6.1 (4.6) 83 (4.8%)
Work, n (%) 65 (4%)
Not working 59 (7%) 7 (8%) 11 (5%) 48 (10%) 125 (8%)
Retired 720 (86%) 77 (88%) 202 (93%) 369 (74%) 1,368 (83%)
Working 58 (7%) 4 (5%) 5 (2%) 82 (16%) 149 (9%)
Educational level, n (%) 205 (12%)
Low 120 (16%) 17 (23%) 39 (20%) 81 (18%) 257 (17%)
Medium 517 (67%) 47 (63%) 126 (63%) 294 (64%) 984 (66%)
High 133 (17%) 11 (15%) 34 (17%) 83 (18%) 261 (17%)
Relationship status, n (%) 22 (1%)
Married† 724 (85%) 66 (75%) 178 (80%) 438 (85%) 1,406 (83%)
Other 132 (15%) 23 (26%) 44 (20%) 80 (15%) 279 (17%)
Have children, n (%) 11 (1%)
Yes 778 (90%) 81 (88%) 201 (89%) 469 (90%) 1,529 (90%)
No 82 (10%) 11 (12%) 24 (11%) 50 (10%) 167 (10%)
Horm ¼ hormonal treatment; RAD ¼ radio-therapy; RP ¼ prostatectomy.
*Treatment following diagnosis of prostate canceresee also the “Statistics” section in the article for more details.
†Including co-habiting respondents.
212 Hald et alformal education (grouped into low, medium, and high levels of
education); (d) employment status (not working, retired, and
working); (e) relationship status (married, divorced, single,
widowed, other; dichotomized into married/co-habiting and
other); and (f) parental status (have children, do not have
children).Prostate Cancer Diagnosis and Treatments
Respondents were asked: (a) if they had been formally diag-
nosed with prostate cancer (yes, no, do not know), (b) when they
had received their prostate cancer diagnosis (year and month),
and (c) what treatments they had received for prostate cancer.
Following Fosså et al5 in 2016, the respondents were grouped
based on their total treatment burden in the following manner.Group 1
The radical prostatectomyeonly group included respondents
who reported to have undergone radical prostatectomy but never
received hormonal treatment, as well as respondents who re-
ported undergoing postoperative radiation therapy, as their
pattern of adverse events did not differ signiﬁcantly from those
who reported undergoing radical prostatectomy but not post-
operative radiation therapy.6Group 2
The radio-therapy-only group included respondents who re-
ported radiation therapy only and had never received hormonal
treatment.Group 3
The hormone treatment group comprised respondents who
previously had been exposed to androgen deprivation therapy or
who were currently undergoing androgen deprivation therapy.
Data for the calculation of treatment-free interval durations were
not available.Group 4
The group receiving no prostatic cancer treatment included
respondents without any treatment following their prostate
cancer diagnosis. No distinction between active surveillance and
watchful waiting was made.Sexuality-Related Variables
To identify the respondents who were sexually active prior to
treatment onset, respondents were asked to respond to the
following statement: “I was no longer sexually active when
starting my treatment (agree, disagree, do not know).” Problems
related to erectile functioning, orgasm, and sexual functioning
were assessed with the following 3 questions using the same stem.
“Have you experienced problems related to your ability to (a)
gain an erection, (b) orgasm, or (c) function sexually?” For these
3 questions, the response options were “yes,” “no,” and “do not
know.” Self-perceived satisfaction with one’s sex life was assessed
using the following question: “Do you agree or disagree with
the following statement about your sex life: Following my
treatment for prostate cancer, I have been satisﬁed with my
sex life (completely disagree, disagree, neither/nor, agree,
completely agree).”Sex Med 2018;6:210e216
Table 2. Sexual problems and sexual satisfaction by treatment group (Ntotal ¼ 1,707)
Variable Horm,* n (%) No treatment,* n (%) RAD,* n (%) RP,* n (%) Total, n (%) Missing n (%)
Erectile problems 72 (4%)
Agree 734 (89%) 58 (69%) 179 (84%) 471 (92%) 1,442 (88%)
Disagree 36 (4%) 12 (14%) 25 (12%) 25 (5%) 98 (6%)
Don’t know 57 (7%) 14 (17%) 8 (4%) 16 (3%) 95 (6%)
Orgasm problems 93 (5%)
Agree 657 (81%) 50 (61%) 167 (78%) 364 (72%) 1,238 (77%)
Disagree 68 (8%) 12 (15%) 32 (15%) 114 (22%) 226 (14%)
Don’t know 87 (11%) 20 (24%) 14 (7%) 29 (6%) 150 (9%)
Problems in sexual functioning 87 (5%)
Agree 706 (86%) 54 (64%) 167 (80%) 430 (84%) 1,357 (84%)
Disagree 37 (5%) 16 (19%) 27 (13%) 45 (9%) 125 (8%)
Don’t know 75 (9%) 15 (18%) 14 (7%) 34 (7%) 138 (9%)
Sexual problems composite† 113 (7%)
Yes 723 (90%) 60 (74%) 180 (87%) 475 (94%) 1,438 (90%)
No 79 (10%) 21 (26%) 26 (13%) 30 (6%) 156 (10%)
Satisﬁed with sex life 75 (4%)
Completely agree 23 (3%) 1 (1%) 7 (3%) 14 (3%) 45 (3%)
Agree 64 (8%) 11 (13%) 22 (10%) 45 (9%) 142 (9%)
Neither/nor 152 (18%) 24 (29%) 39 (18%) 87 (17%) 302 (19%)
Disagree 236 (28%) 14 (17%) 69 (33%) 148 (29%) 467 (29%)
Completely disagree 281 (34%) 22 (27%) 64 (30%) 192 (38%) 559 (34%)
Don’t know 75 (9%) 11 (13%) 10 (5%) 21 (4%) 117 (7%)
Horm ¼ hormonal treatment; RAD ¼ radio-therapy; RP ¼ prostatectomy.
*Treatment following diagnosis of prostate canceresee also the “Statistics” section in the article for more details.
†Composite variable where “Yes” ¼ problems with any 1 or more of the following: (a) erectile functioning, (b) orgasm, (c) self-perceived overall sexual
functioning.
Prostate Cancer and Sexual Problems 213For the logistic regression analyses, the 3 items with the same
stem (ie, items assessing problems related to erectile, orgasmic,
and overall sexual functioning) were used to create a “no sexual
problems” composite variable following correlational and factor
analyses. The correlational analyses showed inter-item correla-
tions of r ¼ 0.46e0.60. Using principal axis factoring, the scree
plot and Kaiser-Guttman rule both indicated that only 1 factor
should be extracted. This factor was found to explain 67.1% of
the variance of the ﬁrst extracted factor, indicating the appro-
priateness of the composite variable.Statistics
Sociodemographic data were summarized using frequencies
or means and SD (as appropriate), stratiﬁed by treatment
groups. Associations between baseline data and the “sexual
problems” composite variable, as well as the “satisfaction with
the sex life” variable, were addressed using logistic regression
analyses. Missing data were imputed prior to analysis using
chained equations, as implemented in the mice statistical
package in R (www.R-project.org). For the sexual function
outcome measure, the response option of “do not know” was
treated as a missing variable and imputed.
Prevalence data for sexual problems and sexual satisfaction
were summarized using frequencies and stratiﬁed by treatment
group (Table 2).Sex Med 2018;6:210e216For the sexual problems composite variable, outcomes were
dichotomized (0 ¼ no sexual problems and 1 ¼ 1 or more sexual
problem). Hence, Table 3 shows the odds ratios for reporting no
sexual problems. For the “satisfaction with my sex life” variable,
outcomes were also dichotomized (0 ¼ completely disagree,
disagree, neither/nor; 1 ¼ agree, completely agree). Analyses
were based on the imputed data using 15 imputations. All ana-
lyses were performed using R, Version 3.3.1.
RESULTS
For treatment group distributions, sociodemographic vari-
ables, and time since diagnosis, please see Table 1.
Table 2 presents the data for problems related to erectile
function, orgasm, and sexual functioning and for respondents’
satisfaction with their sex life following treatment. Sexual
satisfaction data for the no treatment group are presented for
comparison, although the question of sexual satisfaction
targeted sexual satisfaction following the treatment interven-
tion. As shown in the table, across the treatment groups, a clear
majority of men diagnosed with prostate cancer experienced
sexual problems and decreased sexual functioning following
treatment. Speciﬁcally, 69e92% of men reported erectile
problems, 61e81% reported orgasm problems, and 74e94%
reported at least 1 sexual problem or problem related to
sexual functioning. Furthermore, across treatment groups,
Table 3. Odds ratios and 95% CI for sexual problems and
satisfaction with sex life
Variable
No sexual
problems
Satisfaction with
sex life
Treatment group
Horm (reference)* 1 1
No treatment* 3.75 (1.75e8.05)† 1.17 (0.61e2.25)
RAD* 2.91 (1.55e5.47)† 1.24 (0.79e1.94)
RP* 0.90 (1.55e5.47)† 1.21 (0.84e1.75)
Work
Not working
(reference)
1 1
Retired 1.24 (0.38e4.00) 0.66 (0.36e1.23)
Working 1.95 (0.50e7.58) 0.56 (0.24e1.31)
Education
Low (reference) 1 1
Medium 1.24 (0.56e2.72) 0.60 (0.38e0.94)‡
High 1.55 (0.67e3.62) 0.65 (0.37e1.14)
Relationship status
Married/co-habitating
(reference)
1 1
No 1.44 (0.76e2.72) 1.30 (0.86e1.97)
Have children
Yes (reference) 1 1
No 0.71 (0.27e1.86) 1.16 (0.69e1.95)
Age 1.03 (0.98e1.07) 1.05 (1.02e1.08)†
Time since diagnosis 1.00 (0.99e1.00) 1.00 (0.99e1.00)§
Each cell presents odds ratio with 95% CI in parentheses.
Horm ¼ hormonal treatment; RAD ¼ radio-therapy; RP ¼ prostatectomy.
*Treatment following diagnosis of prostate cancereplease see also the
“Statistics” section in the article for more details.
‡P < .05.
§P < .01.
†P < .001.
214 Hald et alonly a minority of respondents (<15%) reported being
satisﬁed with their sexual life, including the respondents who
had not received any kind of treatment following their
diagnosis.
As shown in Table 3, after age, education, time since diag-
nosis, and civil, employment, and parental status were controlled
for, the group of patients who did not receive any prostatic
cancer treatments or radio-therapy treatment was signiﬁcantly
more likely than the hormonal treatment reference group to
report no sexual functioning problems. No signiﬁcant differences
between treatment groups were found for satisfaction with sex
life. However, older age and longer time since diagnosis were
found to be signiﬁcantly correlated with increased satisfaction
with the sex life (P < .01).DISCUSSION
In line with previous research, this study showed a high
prevalence of sexual problems among prostate cancer patients
who were sexually active prior to cancer treatment onset.Speciﬁcally, this study found that the prevalence of ED,
orgasmic problems, and problems related to sexual functioning
ranged from 72e92% across prostate cancer treatment groups.
In comparison, for the group of patients who had not received
prostate cancer treatment, this range was 61e69%. These
ﬁndings indicate that, while sexual problems may be common in
this cohort, men who were sexually active prior to prostate cancer
treatment and receive prostate cancer treatment experience high
rates of sexual problems following treatment.4,6,32 These results,
involving a large Scandinavian sample, corroborate existing
literature in the area involving samples from other cultural
backgrounds and are likely an effect of the prostate cancer
treatments themselves and/or their adverse side effects, such as
fatigue, urinary and bowel problems, and reduced psychological
well-being.12,17,20,32
Generally, the prevalence of sexual problems found in this
study is somewhat elevated compared to the prevalence reported
in other studies involving prostate cancer patients.6,11,14,15,32,33
This discrepancy is likely due to an age effect, as sexual prob-
lems generally increase with age,19,24,34 and the mean age of the
respondents in this study was relatively high. Nevertheless, when
controlling for a variety of variables including age, the group of
patients who did not receive any prostate cancer treatment was
3.75 times more likely than the reference group to report having
no sexual function problems. Although the study design does not
allow for causal inferences, this result indicates a direct effect of
the prostate cancer treatments on the sexual outcomes studied,
extending beyond the effects of age or the other sociodemo-
graphic factors for which we controlled.4,5,7,8
A high proportion of respondents reported dissatisfaction with
their sex life following prostate cancer treatment. This result may
be due to the orgasmic or erectile problems evaluated,20 more
general adverse treatment effects inﬂuencing sexuality,5e7
partner-related issues,35,36 or other sexual problems not
measured here but often reported by prostate cancer patients
following treatment, including reduced sexual desire, lower
sexual interest, and sexually related pain.8,9,18,22 Moreover, it
may also be an effect of the cohort studied as it includes only
men, who were sexually active prior to diagnoses. Hence, for this
cohort sexual problems following treatment may be perceived as
more dissatisfactory as compared to men, who were not sexually
active prior to diagnosis and for whom sexuality may play a
different and perhaps less important role throughout the diag-
nostic and treatment process.
When evaluating the results, the following factors should be
considered. First and foremost, to keep the questionnaire as short
as possible,5 the sexual outcomes studied here were assessed using
non-validated crude indicators. While such indicators are not
unusual in sexual research, they may adversely affect the reli-
ability and validity of the study results or fail to adequately
capture the complexity of the outcomes studied. For example,
“orgasmic dysfunction” is an umbrella term that covers different
problems, including painful orgasm (dysorgasmia), urinarySex Med 2018;6:210e216
Prostate Cancer and Sexual Problems 215leakage during orgasm (climacturia), delayed orgasm (retarded
ejaculation), and absence of orgasm (anorgasmia),18,37 which
were not separately considered in this study. This limitation may
be related to the sexual outcomes studied and/or the key factors
that may indirectly inﬂuence these outcomes (eg, levels of
fatigue, psychological well-being, quality of life, and age). Simi-
larly, this study did not differentiate between different kinds of
ED,38 which may have inﬂuenced the prevalence results of the
study. Second, the study used a self-selected sample, which may
not be representative of sexually active prostate cancer patients at
large.12,17,20,32 Third, although the results were stratiﬁed by
prostate cancer treatments, additional subgroup stratiﬁcations
may further improve the accuracy of the results.12,17 For
example, the type and method of surgery related to radical
prostatectomy have been found to inﬂuence the prevalence of
ED among prostate cancer patients.39CONCLUSION
Despite these limitations, using a large sample of Scandinavian
men, this study underscores a strong clinical need to address the
possibility of sexual problems and reduced sexual satisfaction
among prostate cancer patients who are sexually active prior to
treatment onset, even when these patients are relatively old. For
health care personnel targeting the sexual rehabilitation of pa-
tients, this process may include providing information, concrete
advice, and speciﬁc suggestions; following the PLISSIT model39;
a penile and sexual health and well-being program40; as well as
addressing solo and partnered sexual activity and satisfac-
tion.20,21,31 In this connection, as different kinds of treatments
strategies of prostate cancer are associated with different patterns
of adverse effects over time (eg, urinary incontinence, bowel
problems, and sexual dysfunctions)41 when promoting treatment
decisions that incorporate sexual health and rehabilitation, these
needs to be co-considered. For researchers, similar studies
including cohorts of younger men, probability samples, and
more differentiated outcome measures would further help to
extend and qualify the study ﬁndings.ACKNOWLEDGEMENT
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